IPO filing research

DYADIC INTERNATIONAL INC

Biological Products, (No Diagnostic Substances) · DYAI

follow-on trading filed Nasdaq S-1

DYADIC INTERNATIONAL INC IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-09-11. Current deal snapshot: exchange Nasdaq.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B5 in the pre-IPO sequence.

3,625,000 shares

Common · Exchange Nasdaq · Ticker DYAI · Warrants exercisable at $0.84 per share · Selling stockholders only · Use of proceeds Selling stockholders will resell shares; no proceeds to the company · Flags warrants

2026-09-11 · 0001493152-26-042435

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.88 · 3,625,000 shares · Gross proceeds $2,881,875

Common · Exchange NASDAQ · Ticker DYAI · Warrants to purchase 3,625,000 shares at $0.84 · Use of proceeds Gross proceeds to the company before expenses are $2,881,875 · Underwriters Aegis Capital Corp.

2026-08-13 · 0001493152-26-037870

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

2026-03-06 · 0001493152-26-009176

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B5 and confirms the priced prospectus.

Price $0.95 · 6,052,000 shares · Gross proceeds $5,749,400

Common Stock · Exchange Nasdaq Capital Market · Ticker DYAI · Underwriter Warrants to purchase 302,600 shares at $1.0925 exercise price · Use of proceeds Working capital and general corporate purposes · Underwriters Craig-Hallum Capital Group LLC

2025-07-31 · 0001641172-25-021784

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Common Stock · Exchange Nasdaq Capital Market · Ticker DYAI · warrants to purchase up to 5.0% of the shares of common stock sold in this offering · Use of proceeds working capital and general corporate purposes · Underwriters Craig-Hallum Capital Group LLC

2025-07-30 · 0001641172-25-021545

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2025-04-02 · 9999999995-25-000951

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2024-05-07 · 9999999995-24-001404

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2023-08-25 · 9999999995-23-002495

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows CERT and marks the registration effective.

2020-08-25 · 9999999995-20-002250

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows 8-A12B in the pre-IPO sequence.

2019-04-16 · 0001354457-19-000207

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows RW and registers the class of securities for exchange listing.

2019-04-12 · 0001213809-19-000013

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows RW and ends the active registration process.

2019-01-02 · 0001628280-19-000057

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows 424B3 and ends the active registration process.

2014-10-10 · 0001140361-14-037875

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

5,581,484 shares · Gross proceeds $0.00

of their share · Exchange AMEX · Ticker DIL · 657,732 shares issuable upon exercise of warrants · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, to the extent exercised for cash

2007-01-22 · 0001213809-07-000008

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2007-01-18 · 9999999995-07-000223

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

28,369,878 shares

Common Stock · Warrants exercisable at $5.50 and $3.33 per share · Selling stockholders only · Use of proceeds Proceeds from the sale of shares will be received by the selling stockholders, with no proceeds going to the company · Flags warrants

2006-07-07 · 0001213809-06-000038

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

28,369,878 shares

of the other holders of our outstanding share · Exchange American Stock Exchange · Ticker DIL · Shares include options and warrants to purchase common stock · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, and the company will not receive any proceeds

2005-08-12 · 0001144204-05-024990

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 8-A12B and confirms the priced prospectus.

28,369,878 shares

of the proceeds from the sale of the share · Exchange OTC Bulletin Board · Ticker DYAD.OB · Each Investment Unit consists of one share of common stock and one warrant to purchase one share at $5.50 per share for every two units · Warrants to purchase common stock at $5.50 per share, exercisable for five years · Selling stockholders only · Use of proceeds Selling stockholders with no issuer proceeds · Flags units, warrants

2005-05-24 · 0001144204-05-017012

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows 424B3 and registers the class of securities for exchange listing.

2005-05-24 · 0001144204-05-016934

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

28,369,878 shares

of the proceeds from the sale of the share · Exchange OTC Bulletin Board · Ticker DYAD.OB · Selling stockholders only · Use of proceeds No proceeds to the company; selling stockholders bear their own expenses

2005-05-09 · 0001144204-05-014454

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

28,369,878 shares

of the proceeds from the sale of the share · Exchange OTC · Ticker DYAD.OB · Proceeds from warrant exercises · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale

2005-03-03 · 0001144204-05-006610

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

28,369,878 shares

Common Stock · Exchange OTC · Ticker DYAD.OB · Selling stockholders only · Use of proceeds selling stockholders will receive all proceeds

Dyadic International, Inc. operates through three segments: U.S. (enzyme products, bio-molecules, and proprietary technology), Hong Kong (chemical and enzyme products for textiles/pulp), and Netherlands (R&D activities). The filing includes unaudited pro forma financials reflecting a November 2004 equity offering, debt cancellation via the Mark A. Emalfarb Trust, and merger with a CCP Worldwide subsidiary. The company reports operating losses, significant tax liabilities in foreign jurisdictions, and a 100% valuation allowance on U.S. deferred tax assets due to uncertainty about future profitability. Restatements of 2003 financials corrected foreign currency transaction errors affecting inventory and net loss.

2005-02-01 · 0001144204-05-002909

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

First tracked pre-IPO filing for this issuer.

CCP Worldwide, Inc. is preparing for an IPO, with financial statements showing significant losses, reliance on major customers, and no inventory due to direct shipment practices. The company, incorporated in 2002, has a retained deficit and negative cash flow, with operations focused on packaging materials for U.S. customers. The filing includes audited financials through 2002 and unaudited data through September 2003.

2003-12-29 · 0001144204-03-008782

Comparable Deals

20 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 20 using nearest neighbors.

Showing top 8 by similarity.

+6.4%

Median day-1

60%

Above issue

+10.6%

Median week-1

-16.7%

Downside (p10)

Attovia Therapeutics, Inc. ATTO

2026-08-05 $269M Day 1: +28.8% Wk 1: +9.7%

same SICrecent IPO

Scribe Therapeutics, Inc. SCTX

2026-07-24 $129M Day 1: +44.3% Wk 1: +37.2%

same SICrecent IPO

Odyssey Therapeutics, Inc. ODTX

2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%

same SICrecent IPO

Hemab Therapeutics Holdings, Inc. COAG

2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%

same SICrecent IPO

Vogenx, Inc. VOGX

2026-08-12 $81M Day 1: +0.0% Wk 1: +51.9%

same SIC grouprecent IPO

BlossomHill Therapeutics, Inc. BLSM

2026-08-07 $150M Day 1: +0.0% Wk 1: +2.2%

same SIC grouprecent IPO

Latigo Biotherapeutics, Inc. LTGO

2026-08-07 $346M Day 1: +1.4% Wk 1: +11.4%

same SIC grouprecent IPO

Braveheart Bio, Inc. BRVE

2026-08-06 $383M Day 1: +65.6% Wk 1: +45.3%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.